CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
Provided herein are methods for selecting a cancer patient for anti-CTLA-4 immunotherapy, or predicting whether a cancer patient will respond to anti-CTLA4 immunotherapy, based on measured levels of CXCL1 1 and/or sMICA. Such methods are useful for determining whether an anti-CTLA-4 immunotherapy is likely to improve overall survival of a cancer patient. Also provided herein are methods of treating a cancer patient with an anti-CTLA-4 immunotherapy, wherein the patient is first tested for levels of CXCL1 1 and/or sMICA. Also provided are methods for treating a cancer patient with a CXCL1 1 antagonist or sMICA ant agonist alone, or in combination with each other and/or with additional anti-cancer agents, such as a CTLA-4 antagonist.
BRISTOL-MYERS SQUIBB COMPANY (Princeton, NJ); Providence Health & Services (Portland, OR)
US 20180246113 A1
Bahjat, Keith Sandoon; Hoen, Helena Maria; Koguchi, Yoshinobu; and Korman, Alan J., "CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy" (2021). Technology Transfer - Patents. 60.